Výsledky vyhledávání - "Xavier González Farré"

Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC)

Autor: Meritxell Bellet, Serafin Morales, Ariadna Gasol, Kepa Amillano, Nuria Chic, Xavier González-Farré, Patricia Villagrasa, Laia Paré, Claudette Falato, Paolo Nuciforo, Débora Martínez, Juan M Ferrero-Cafiero, Tomás Pascual, Aleix Prat, Carol Lange, Cristina Saura

Publikováno v: Cancer Research. 82:P1-07

Background PgR expression is a biomarker of ER functionality, cellular progression to malignancy, and response to endocrine therapy (ET) in HR+ BC. Onapristone (ONA), a type 1 antiprogestin, was shown to have a single agent anti-tumor activity in pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e2b150e6f103c9fcc2979764a6d5c83
https://doi.org/10.1158/1538-7445.sabcs21-p1-07-02

Zobrazit plný text záznamu

Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis

Autor: Tomás Pascual, Maria Vidal, Mafalda Oliveira, Juan M Cejalvo, Estela Vega, Esther Sanfeliu, Sergi Ganau, Ana Julve, Esther Zamora, Ignacio Miranda, Ana Delgado, Begoña Bermejo, Luis de la Cruz, Claudette Falato, Manel Juan, Juan M Ferrero-Cafiero, Xavier González-Farré, Patricia Villagrasa, Aleix Prat

Publikováno v: Cancer Research. 82:P2-14

Background Residual disease (RD) following neoadjuvant chemotherapy (NAC) in early HER2 negative breast cancer (BC) remains an unmet medical need. We hypothesized that combining T-VEC with Atezolizumab may offer clinical benefit in terms of residual

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a3a842a2d08903691ffb220d8c7aae5e
https://doi.org/10.1158/1538-7445.sabcs21-p2-14-13

Zobrazit plný text záznamu

Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)

Publikováno v: Cancer Research. 82:OT2-27

Background HR+/HER2-negative BC represents ∼70% of all newly diagnosed breast tumors. BC is a clinically and biologically heterogeneous disease where intrinsic subtypes play a role. Non-luminal subtypes within HR+/HER2-negative disease do not benef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12b5337c3dc8f6e69463634dc58b2487
https://doi.org/10.1158/1538-7445.sabcs21-ot2-27-01

Zobrazit plný text záznamu

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Publikováno v: LANCET ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Ann Transl Med
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
The Lancet. Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA

Summary Background In hormone receptor-positive, HER2-negative early stage breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could represent an alternative to multiagent chemotherapy. We aimed t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b99ef44481f29a81975cb0e266b807
https://doi.org/10.1016/s1470-2045(19)30786-7

Zobrazit plný text záznamu

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study

Autor: Fernando Salvador Moreno, Laura Murillo, Luis A. Fernández-Morales, Carlos Jara-Sanchez, Ana González, Mª del Mar Angulo, Vicente Carañana, Manuel Ramos, Mª Isabel Casas, José A. García-Sáenz, Antonio Llombart-Cussac, Ana I. Garcia-Mace, Xavier González-Farré, Serafin Morales, Elsa Dalmau, Lourdes Calvo, Mª Carmen Cámara, Eva Carrasco

Publikováno v: European journal of cancer (Oxford, England : 1990). 58

Background Docetaxel–cyclophosphamide (TC) has become a common regimen in moderate-high-risk early breast cancer (EBC), but the incidence of chemotherapy-induced nausea and vomiting (CINV) with this regimen is not well established. This trial inves

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c27ff7ea7063301920f52aef74d05782
https://pubmed.ncbi.nlm.nih.gov/26994459

Zobrazit plný text záznamu

Individualization of treatment strategies

Autor: Javier Cortés Castán, Sonia González Jiménez, Alicia García Arias, Laura Jolis López, Gemma Viñas Villaró, Xavier González Farré, Rafael Villanueva Vázquez, Adela Fernandez Ortega, Cristina Saura Manich

Publikováno v: Advances in therapy. 28

This section focuses on different aspects of the individualization of hormone treatment in breast cancer. This includes tumor-related biological factors such as expression of hormone receptors, HER-2, and Ki-67; host-related factors such as CYP2D6 or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a3cb0402148d869f89079686422bc8d
https://pubmed.ncbi.nlm.nih.gov/21922393

Zobrazit plný text záznamu

Akademický článek

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

Publikováno v: PLoS ONE, Vol 9, Iss 10, p e109611 (2014)

BackgroundTrastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progr

Externí odkaz: https://doaj.org/article/96570f731e5b47eda63fe7f906eaa872

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání